Physician profile
Benjamin T Bailey
NPI 1740620103
$2,309.87
in general payments reported to CMS, 2019-2025
29 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $350 · 2022: $297 · 2023: $223 · 2024: $454 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,184.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $452.56 | 2019-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Novo Nordisk INC | $283.47 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $229.30 | 2022-2025 | Ubrelvy |
| Pfizer INC. | $200.85 | 2019-2025 | |
| Glaxosmithkline, LLC. | $154.32 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $145.77 | 2020-2025 | Zepbound, Jardiance, Mounjaro |
| Welch Allyn | $99.98 | 2020 | |
| Dexcom, INC. | $88.64 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $73.49 | 2020-2024 | Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $58.41 | 2022 | |
| Xeris Pharmaceuticals, INC. | $53.33 | 2024-2025 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $44.54 | 2020 | |
| Boston Scientific Corporation | $39.48 | 2024-2025 | General - Erectile Dysfunction |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.48 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $37.47 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $35.29 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $34.95 | 2024-2025 | Eliquis |
| Merck Sharp & Dohme LLC | $31.90 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Exact Sciences Corporation | $31.65 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $24.94 | 2025 | Voquezna |
| Amarin Pharma, INC. | $18.87 | 2020 | |
| Insulet Corporation | $18.05 | 2024 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.98 | 2023 | Xifaxan |
| Dynavax Technologies Corporation | $17.85 | 2025 | Heplisav-B |
| Seqirus USA INC | $17.19 | 2025 | Fluad, Flucelvax |
| Alexion Pharmaceuticals, INC. | $16.88 | 2023 | Strensiq |
| Daiichi Sankyo INC. | $15.62 | 2019 | |
| Sanofi Pasteur INC. | $15.00 | 2025 | |
| Allergan, INC. | $12.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.